Abstract
Biomedical innovation is the process of transforming scientific discoveries into vaccines, biodiagnostic reagents, and genetically-engineered drugs and therapies that save or improve patients’ lives. This type of process is typical of translational research, yet a great many efforts in the field of biomedical research fail to deliver the desired outcomes, and some even result in an enormous waste of time and resources. Long R&D periods and inefficient methods of transforming knowledge from basic scientific findings into practical clinical tools are the main reasons for failure. Understanding how scientific research co-evolves with technological development could provide novel and profound insights along the path of biomedical innovation. However, there are not many researches to deal with this aspect in recent years. Therefore, this paper presents a framework that traces the history of USFDA approved drugs in granular detail. Using scientific papers and patents as data sources, we use qualitative and quantitative techniques to analyze the innovation process from the inception of discovery into a marketable pharmaceutical. The focus of our analysis is the information found in science and technology documents, which can be an indicator of the interplays between discovery and development in a translational research process. Entropy statistics then provide an indication of the shared information for maximum utility in the analysis. The analysis results, which include expert judgments, could drive possible future insights into biomedical innovation with implications for policymakers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
